Data from 2 studies involving 53 people with T2DM was analysed to determine the impact of EECP therapy compared with placebo at 7–12 weeks after completion of therapy.9,10 Compared with patients in the placebo or passive control group, patients receiving EECP therapy had significantly lower levels of HbA1C (MD -0.98%, 95% CI -1.22, -0.74; p<0.00001; I2=0% [LH]; HCE; Figure 5a) and FPG (MD -0.66 mmol/l, 95% CI -1.05, -0.28; p=0.0008; I2=0% [LH]; Figure 5b). Here, PLOD1 is linked to type 2 diabetes mellitus.